Safety and Tolerance of a Partly Fermented Infant Formula With Prebiotic Oligosaccharides in Healthy Infants

NCT ID: NCT03476889

Last Updated: 2018-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

252 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-19

Study Completion Date

2021-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomised, controlled, double-blind, parallel group, multi-country study to investigate the safety and tolerance of a partly fermented infant formula containing prebiotic oligosaccharides in healthy term infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Growth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Cows milk based infant formula containing fermented infant formula and prebiotic oligosaccharides

Group Type EXPERIMENTAL

Infant formula

Intervention Type OTHER

Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.

Control

Cows milk based infant formula containing prebiotic oligosaccharides (commercially available Aptamil ProNutra)

Group Type ACTIVE_COMPARATOR

Infant formula

Intervention Type OTHER

Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.

Breastfed reference

Exclusively breastfed from birth to study completion

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Infant formula

Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy, singleton, term infants
2. Aged ≤14 days at randomisation/enrolment
3. Birth weight within normal range for gestational age and sex
4. Head circumference at birth within normal range for age and sex
5. Maternal age ≥18 years at birth;
6. Intervention arms: exclusively formula fed at randomisation (infants of mothers who autonomously chose not to breastfeed for any reason before their infant is ≤14 days of age, and who intend to exclusively formula feed until their infant is at least 17 weeks of age); OR Breastfed reference arm: exclusively breastfed at enrolment (infants of mothers who intend to exclusively breastfeed until their infant is at least 17 weeks of age);
7. Written informed consent from parent(s) and/or legal guardian(s), who themselves are aged ≥18 years.

Exclusion Criteria

1. Infants who require to be fed a special diet other than standard cow's milk based infant formula;
2. Infants known or suspected to have cow's milk allergy, soy allergy and/or lactose intolerance;
3. Infants known or suspected to have current or previous illnesses/conditions or interventions which could interfere with the study or its outcome parameters, as per the clinical judgement of the Investigator;
4. Infants with known or suspected congenital diseases or malformations which could interfere with the study or its outcome parameters (including, but not limited to: GI malformations, congenital immunodeficiency), as per the clinical judgement of the Investigator;
5. Infants with previous, current or intended participation in any other clinical study involving investigational or marketed products;
6. Incapability of infants' parents/legally acceptable representatives to comply with study protocol or Investigator's uncertainty about the willingness or ability of the parent(s)/legally acceptable representative(s) to comply with the protocol requirements;
7. Infants born from mothers with significant medical conditions during pregnancy that might interfere with the study or known to affect intra-uterine growth (e.g. placenta previa, pre-eclampsia, eclampsia, gestational diabetes requiring insulin or oral medication) as per Investigator's judgement.

Criteria for lactating mothers of subjects in the breastfed reference arm:
8. Lactating women who are currently participating or intend to participate in any other clinical study involving investigational products. Participation in purely observational studies is permitted;
9. Lactating women known to suffer from hepatitis B or human immunodeficiency virus;
10. Lactating women known to have any other significant medical condition(s) which might interfere with the study or its outcome parameters (breast abscess or mastitis which could interfere with lactation, or other clinically relevant infections, or consumption of medication/substances which could impact the infants' growth), as per the clinical judgement of the Investigator;
11. Lactating women who intend to feed their infants with a combination of human milk and infant formula.
Minimum Eligible Age

1 Day

Maximum Eligible Age

14 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nutricia Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Poliklinika Ginekologiczno-Położnicza Sp. z o.o. Sp. k.

Bialystok, , Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Poland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jan van der Mooren, MD, PhD

Role: CONTACT

+31 30 295000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

M Arciszewska

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EBB17TA14644

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotic Formula and Infant Growth
NCT01476397 COMPLETED NA
Safety and Efficacy Study
NCT02670863 COMPLETED NA
Colonisation Resistance Study
NCT01507935 WITHDRAWN PHASE2
Formula Tolerance of Term Infants
NCT04915937 COMPLETED NA